THE USE OF GLP-1 AGONISTS LIRAGLUTIDE, SEMAGLUTIDE AND TIRZEPATIDE IN THE TREATMENT OF OBESITY: A LITERATURE REVIEW
DOI:
https://doi.org/10.47820/recima21.v4i4.2950Keywords:
Drug Therapy, Obesity, GLP-1Abstract
Obesity is a chronic disease whose prevalence has been consistently rising. Farmacotherapy presents itself as an important adjuvant therapy for weight management. GLP-1 agonists are one of the drug classes studied for promoting weight loss. Development: The drugs from this class mimic the action of GLP-1, an endogenous incretine that binds to receptors located in the gastrointestinal tract and central nervous system, increasing insuline secretion and satiety. Liraglutide and semaglutide are two of the main drugs from this class, and tirzepatide is a new medication which has the additional action of being a GIP agonist. In the clinical trials that compared GLP-1 agonists to placebo, it was observed that semaglutide was associated with more weight loss than liraglutide, and this loss persisted for a longer period of time. Tirzepatide demonstrated an even more relevant result, but it's use is still not approved for obesity treatment due to the necessity of more trials testing the drug for this purpose. Final considerations: All three drugs studied were effective in promoting clinically relevant weight loss, with additional improvement in glicemic control cardiometabolic risk.
Downloads
References
- APOVIAN, C. M. Obesity: definition, comorbidities, causes, and burden. The American Journal of Managed Care, v. 22, n. 7, 2016.
- BARBOSA, A. M. S.; REIS, F. R. DA S.; MARQUEZ, C. O. Atenção farmacêutica no tratamento da obesidade envolvendo os análogos do Glucagon-like peptide 1 (GPL-1). Research, Society and Development, v. 11, n. 7, 2022.
- AASETH, J. et al. Diets and drugs for weight loss and health in obesity – An update. Biomedicine & Pharmacotherapy, v. 140, p. 111789, ago.
- JASTREBOFF, Ania M. et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine, v. 387, p. 205-216, 21 jul. 2022. DOI 10.1056/NEJMoa2206038. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038.
- PI-SUNYER, Xavier; ASTRUP, Arne; FUJIOKA, Ken; et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, v. 373, n. 1, p. 11–22, 2015. Disponível em: https://www.nejm.org/doi/10.1056/NEJMoa1411892. Acesso em: 06 set. 2022.
- RUBINO, Domenica et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, [s. l.], v. 325, p. 1–12, 23 mar. 2021. DOI 10.1001/jama.2021.3224. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988425/.
- WADDEN, Thomas A. et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA, [s. l.], v. 325, p. 1–11, 24 fev. 2021. DOI 10.1001/jama.2021.1831. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905697/.
- COSTA, I. M. et al. Uso de análogos de GLP-1 no tratamento da obesidade: uma revisão narrativa. Brazilian Journal of Health Review, v. 4, n. 2, p. 4236–4247, 2021.
- NIGRO A. H. L. et al. MEDICAMENTOS UTILIZADOS NO TRATAMENTO DA OBESIDADE: REVISÃO DA LITERATURA. International Journal of Health Management Review, v. 7, n. 3, 2021.
- GUIMARÃES, B. C. DE S. et al. Evidências cientificas sobre o uso de tirzepatida como tratamento da obesidade. Brazilian Journal of Health Review, v. 5, n. 4, p. 13632–13643, 2022.
- WILLARD, F. S. et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, v. 5, n. 17, 2020.
- NETO, Paulo J. S. N.; SANTOS, Everson V. L. Uso da liraglutida como tratamento para obesidade: um estudo bibliométrico. Brazilian Journals Publicações de Periódicos, Paraná, vol. 7, n. 6, 2021. Disponível em: https://brazilianjournals.com/ojs/index.php/BRJD/article/view/30855. Acesso em: 06 de set. de 2022
- NERES, Milena; NETTO, Pedro Antônio; GUSMÃO, Rodolfo Vitor. A liraglutida no tratamento da obesidade. Diário Oficial da União, 2016. Disponível em: https://facunicamps.edu.br/cms/upload/repositorio_documentos/58_A%20LIRAGLUTIDA%20NO%20TRATAMENTO%20DA%20OBESIDADE.pdf. Acesso em: 06 de set. de 2022.
- HUSAIN , Mansoor et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, [s. l.], 29 ago. 2019. DOI 10.1056/NEJMoa1901118. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa1901118#article_citing_articles.
- PERREAULT, Leigh. Obesity in adults: drug therapy. UpToDate. 2022. Disponível em: https://www.uptodate.com/contents/obesity-in-adults-drug-therapy?search=an%C3%A1logos%20de%20GLP1%20e%20perda%20de%20peso&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H4233015682.
- WILDING, John P.H. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, [s. l.], v. 384, p. 989-1002, 18 mar. 2021. DOI 10.1056/NEJMoa2032183. Disponível em: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2023 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.
